Estee Lauder signed Atropos to develop anti-aging personal care ingredients

Recently, Estee Lauder announced that it has signed a joint cooperation agreement with biotechnology company Atropos Therapeutics to identify and develop chemicals that regulate aging. The focus of the joint development will be to find plant-derived senomodulators that can be used in personal care products.

Atropos Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-aging therapies. Atropos's patented platform can identify chemicals that regulate the formation of senescent cells. These substances are very useful for beauty, especially anti-aging and cancer research.

Dr. Andrew Koff, founder of Atropos Therapeutics, said: "The collaboration with Estee Lauder has complemented our ability to identify target substances through high-content screening. We can also use artificial intelligence-based drug design to interfere with aging and aging activities."

Tom Mammone, Vice President of Skin Physiology and Pharmacology at Estée Lauder, commented: "Atropos' in-depth knowledge of aging modifiers and its unique and effective identification method will be closely integrated with our expertise in the field of natural products. Plant-derived senosuppressors will also Bring huge commercial potential."

The field of aging drugs related to the concept of elegant aging is considered to be the next important field in the field of skin care, and raw materials manufacturers have begun to introduce active ingredients in this field. For example, the Swiss plant ingredient company Mibelle launched Alpine Rose Active this year, which is designed to remove senescent cells that accelerate skin aging from aging or stressed skin tissues.